In Brief: InnoCare’s BTK Inhibitor For SLE Hits Primary Endpoint In World-First

 
• By Dexter Jie Yan
  
InnoCare has scored the first clinical win for a BTK inhibitor in a mid-stage clinical study in systemic lupus erythematosus. (Shutterstock)

More from Clinical Trials

More from R&D